Home›Clinical trials›Alabama

GLP-1 clinical trials in Alabama: 18 recruiting now

22 sites in 7 Alabama cities. Registry checked October 16, 2026.

Screening for a study can take weeks. Two cash programs to check.

No insurance needed.

  1. SnagRx$99 a monthcompounded semaglutideCheck price →SnagRx's homepage shows its 12-month prepaid prices first
  2. Medvi$299 a monthFirst month $179compounded semaglutideCheck price →Straight to MEDVi's GLP-1 sign-up

Weight-loss studies (5)

Weight-loss study of cagrisema

Where: Birmingham and Pelham

What: Tests whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

Free to join

Who can join: Adults 18+ with obesity, BMI 35+.

Study record on ClinicalTrials.gov

Uni of Alabama at Birmingham, Birmingham

Cahaba Research, Pelham

Weight-loss study of maridebart cafraglutide

Where: Pelham

What: Tests whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

Free to join

Who can join: Adults 18+ with obesity or overweight, BMI 25+.

Study record on ClinicalTrials.gov

Cahaba Research, Inc., Pelham

Weight-loss study of semaglutide

Where: Birmingham

What: Tests whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

Free to join

Who can join: Adults 18+ who are overweight, BMI 27+.

Study record on ClinicalTrials.gov

Uni of Alabama at Birmingham, Birmingham

Show 2 more studies

Weight-loss study of tirzepatide

Where: Birmingham

What: Tests whether a GLP-1 and GIP medicine, tirzepatide, can help people with obesity lose weight.

Free to join

Who can join: Adults 18+ with obesity.

Study record on ClinicalTrials.gov

University of Alabama at Birmingham, Birmingham

Weight-loss study of olatorepatide

Where: Mobile

What: Tests whether a GLP-1 and GIP medicine from Regeneron Pharmaceuticals, olatorepatide, can help people lose weight.

Free to join

Who can join: Adults 18+ with obesity or overweight, BMI 27+.

Study record on ClinicalTrials.gov

AMR Clinical - Mobile, Mobile

Type 2 diabetes studies (4)

Type 2 diabetes study of semaglutide

Where: Birmingham

What: Tests whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

Free to join

Who can join: Adults 18+ with type 2 diabetes, BMI 23+.

Study record on ClinicalTrials.gov

Research Site, Birmingham

Type 2 diabetes study of survodutide

Where: Birmingham

What: Tests whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

Free to join

Who can join: Adults 18+ with type 2 diabetes, BMI 23+.

Call the site: 833-602-2368Study record on ClinicalTrials.gov

Cahaba Research, Inc. - Trussville Location, Birmingham. 833-602-2368

Type 2 diabetes study of icovamenib

Where: Birmingham

What: Tests whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

Free to join

Who can join: Adults 18 to 70 with type 2 diabetes, BMI 25+.

Study record on ClinicalTrials.gov

Central Research Associates, LLC dba Flourish Research, Birmingham

Show 1 more study

Type 2 diabetes study of UBT251

Where: Birmingham

What: Tests whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

Free to join

Who can join: Adults 18 to 75 with type 2 diabetes.

Study record on ClinicalTrials.gov

Flourish Research, Birmingham

Other GLP-1 studies in Alabama (9)

Stress urinary incontinence (bladder leaks) study of orforglipron

Where: Birmingham and Mobile

What: Tests whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

Free to join

Who can join: Adults 18+, women only with stress urinary incontinence (bladder leaks), BMI 27+.

Study record on ClinicalTrials.gov

University of Alabama -The Kirklin Clinic, Birmingham

AMR Clinical, Mobile

Fatty liver disease with liver scarring study of survodutide

Where: Birmingham

What: Tests whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

Free to join

Who can join: Adults 18+ with fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

Call the site: 833-602-2368Study record on ClinicalTrials.gov

University of Alabama at Birmingham, Birmingham. 833-602-2368

Show 6 more studies

Ulcerative colitis study of tirzepatide

Where: Dothan

What: Tests whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

Free to join

Who can join: Adults 18 to 70 with ulcerative colitis, BMI 27+.

Call the site: 334-836-1212Study record on ClinicalTrials.gov

Digestive Health Specialists, Dothan. 334-836-1212

Fatty liver disease (MASLD) study of retatrutide

Where: Tuscaloosa

What: Tests whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

Free to join

Who can join: Adults 18+ with fatty liver disease (MASLD), BMI 25+.

Call the site: 205-331-4963Study record on ClinicalTrials.gov

MFA Clinical Research, Tuscaloosa. 205-331-4963

Peripheral artery disease study of orforglipron

Where: Birmingham

What: Tests whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

Free to join

Who can join: Adults 18+ with peripheral artery disease (poor blood flow in the legs), BMI 23+.

Study record on ClinicalTrials.gov

St. Vincent's Birmingham Hospital, Birmingham

Source: ClinicalTrials.gov, the federal registry, read October 16, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

Written and edited by GLP ChartAbout this siteContact
Why you can trust GLP Chart. Same scoring framework applied to every program, and payment never changes a score. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.